Filing Overview
Rani Therapeutics Holdings, Inc. filed a Form 8-K under Item 5.07 regarding its annual meeting of stockholders held on May 25, 2022. The report was signed on May 26, 2022. The filing does not present quarterly or annual operating results.
Key Financial and Capitalization Information
- As of the March 30, 2022 record date, 24,387,030 shares of Class A common stock and 24,773,286 shares of Class B common stock were outstanding and entitled to vote.
- Class A common stock carries one vote per share; Class B common stock carries ten votes per share. Both classes voted together as a single class.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial metrics.
Material Meeting Results
- All nine director nominees were elected to serve until the 2023 annual meeting or until their successors are elected and qualified. Each nominee was elected by a majority of votes cast.
- Votes for the director nominees ranged from 236,182,478 to 236,321,656; votes withheld ranged from 17,693 to 156,871. Broker non-votes totaled 2,702,155 for each nominee.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- The auditor appointment received 239,007,220 votes for, 27,533 against, and 6,751 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, operating outlook, risk updates, contingencies, or unusual financial items. It is limited to annual-meeting voting results and auditor ratification.
Investor Verification Items
- Verify the voting power implications of the dual-class share structure, particularly the ten-votes-per-share Class B stock.
- Review the company’s proxy statement filed April 13, 2022 for the detailed proposal descriptions and director information.
- Confirm subsequent filings for any changes to the board, auditor, capital structure, or financial condition.